Eye Disease & Ophthalmology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)

This Phase 4 trial is focusing on faricimab injections for South Asian patients with diabetic macular edema, a condition causing vision loss due to diabetes-related swelling in the eye. This study is important because it addresses a group that has been underrepresented in previous research, aiming to find out how well faricimab improves vision and how long its effects last. The results, expected by week 88, may offer a more tailored treatment option for patients in this high-risk community.

FIGHT-RP 1 Extension Study

This early-phase trial is testing oral N-acetylcysteine (NAC), an antioxidant, for people with retinitis pigmentosa, a condition that slowly reduces sight over time. The study is primarily checking the safety and tolerability of NAC while exploring whether it can protect eye cells and slow vision loss. If successful, this could lead to a new way to help patients maintain their vision for longer.

A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Amblyopia

This trial is exploring a home-based visual training program using simple computer exercises to help adults with amblyopia, often called lazy eye. Traditionally, treatments for amblyopia have focused on children, but this study is testing whether adults can also improve their vision with a 12-week course of training. This could open new doors for adult patients looking for non-invasive ways to enhance their eyesight.

Combining Noninvasive Brain Stimulation and Augmented Reality-based Dichoptic Therapy for Treating Amblyopic Adults

This study is combining two innovative treatments—noninvasive brain stimulation and augmented reality vision therapy—to improve vision in adults with anisometropic amblyopia. By working on both the brain and the eyes, the therapy aims to boost visual function through 10 weeks of sessions. This approach may provide a new option for adults who have struggled with limited treatment choices for lazy eye.

Validation of the Artificial Intelligence Subsystem of the DDART Medical Device for the Automated Detection of Lesions Compatible With Diabetic Retinopathy in a Random Sample of Retinal Fundus Photographs

This trial is testing an artificial intelligence system that can automatically detect diabetic retinopathy lesions from retinal images. Early detection is key to preventing vision loss in people with diabetes, and this technology could make screening faster and more accessible, especially for large populations. The study plans to recruit 2000 participants in Greece to see how well the AI performs in real-world settings.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.